title: Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience.
abstract: Invasive pulmonary aspergillosis (IPA) is one of the major causes of morbidity and mortality in severely immunocompromised patients, but recently several authors have reported the occurrence of IPA in liver cirrhosis, chronic obstructive pulmonary disease (COPD) patients, most of whom, but not all, were receiving steroid treatment, with a very high mortality rate. The detection of galactomannan performed in respiratory specimens is a new valuable test for the diagnosis of probable IPA, even in non-neutropenic high risk patients. Since the frequency and clinical impact of IPA in non-hematologic patients is not well known, it seemed rational to us to attempt a prospective study evaluating all patients hospitalized in a university hospital for whom an infectious Diseases consultation was required. This 14-month survey in our hospital, using recently recommended diagnostic criteria, seems to suggest an emerging role of IPA in these patients who may have a higher mortality rate than their neutropenic peers, and provides preliminary evidence that early diagnosis and prompt initiation of antifungal therapy may improve the ultimate outcome of their IPA.
authors: Internal Medicine Unit, Department of Public Health and Infectious Diseases, Policlinico Umberto I, University Sapienza, Rome, Italy.
authors: A
authors: A
authors: Russo
authors: M
authors: M
authors: Falcone
authors: A
authors: A
authors: Vena
authors: C
authors: C
authors: Venditti
authors: C
authors: C
authors: Mancini
authors: A
authors: A
authors: Morelli
authors: M
authors: M
authors: Venditti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D001230:Aspergillus / Q000145:classification / Q000302:isolation & purification* / Q000378:metabolism; D001231:Aspergillus flavus / Q000145:classification / Q000302:isolation & purification / Q000378:metabolism; D001232:Aspergillus fumigatus / Q000145:classification / Q000302:isolation & purification / Q000378:metabolism; D015897:Comorbidity; D042241:Early Diagnosis; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006757:Hospital Units; D006785:Hospitals, University; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D007558:Italy / Q000453:epidemiology; D007958:Leukocyte Count; D008297:Male; D008351:Mannans / Q000378:metabolism; D008875:Middle Aged; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D008351:Mannans; D011743:Pyrimidines; D014230:Triazoles; C012990:galactomannan; D065819:Voriconazole; D005690:Galactose